Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma

IF 3.4 Q2 PHARMACOLOGY & PHARMACY

Future Journal of Pharmaceutical Sciences Pub Date : 2025-02-05 DOI:10.1186/s43094-025-00768-9

Singh Shreya, Debadatta Mohapatra, Gaurav Gopal Naik, Pooja Kathait, Soki Malang, Pradeep Patel, Shambhavi, Gulzar Alam, Alakh N. Sahu

{"title":"Cancer multi-omics-based differential expression analysis and prognostic potential of identified hub targets of myco-metabolites for breast carcinoma and lung carcinoma","authors":"Singh Shreya, Debadatta Mohapatra, Gaurav Gopal Naik, Pooja Kathait, Soki Malang, Pradeep Patel,  Shambhavi, Gulzar Alam, Alakh N. Sahu","doi":"10.1186/s43094-025-00768-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Breast carcinoma (BC) and lung carcinoma (LC) have the highest incidence and mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC and LC were identified through network pharmacology. In the present work, web servers UALCAN, GEPIA2, and KM plotter were used to explore the genomic and proteomic expression of these hub targets, along with their prognosis potential in BC and LC.</p><h3>Results</h3><p>Differential hub targets SRC, MAPK3, PTPN11, JAK2, ESR1, and HAP900A1 for BC and PTPN11, JAK2, ESR1, EGFR, and MAPK3 for LC, showed good prognostic potentials. Collectively, PTPN11, JAK2, and ESR1 were overlapped differential expressed hub targets involved in the significantly good prognosis of both carcinoma.</p><h3>Conclusion</h3><p>These differentially expressed hub targets may be taken into account for future BC and LC treatments due to their strong prognostic potential.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00768-9","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00768-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Breast carcinoma (BC) and lung carcinoma (LC) have the highest incidence and mortality rates worldwide. In prior work, studied sample hub targets contributing to anticancer potential against BC and LC were identified through network pharmacology. In the present work, web servers UALCAN, GEPIA2, and KM plotter were used to explore the genomic and proteomic expression of these hub targets, along with their prognosis potential in BC and LC.

Results

Differential hub targets SRC, MAPK3, PTPN11, JAK2, ESR1, and HAP900A1 for BC and PTPN11, JAK2, ESR1, EGFR, and MAPK3 for LC, showed good prognostic potentials. Collectively, PTPN11, JAK2, and ESR1 were overlapped differential expressed hub targets involved in the significantly good prognosis of both carcinoma.

Conclusion

These differentially expressed hub targets may be taken into account for future BC and LC treatments due to their strong prognostic potential.

查看原文本刊更多论文

基于肿瘤多组学的乳腺癌和肺癌真菌代谢物中心靶点的差异表达分析和预后潜力

背景乳腺癌（BC）和肺癌（LC）是世界范围内发病率和死亡率最高的两种癌症。在之前的工作中，通过网络药理学鉴定了对BC和LC具有抗癌潜力的研究样本中心靶点。在本研究中，我们使用web服务器UALCAN、GEPIA2和KM绘图仪来研究这些枢纽靶点的基因组和蛋白质组学表达，以及它们在BC和LC中的预后潜力。结果BC的差异中心靶点SRC、MAPK3、PTPN11、JAK2、ESR1和HAP900A1和LC的差异中心靶点PTPN11、JAK2、ESR1、EGFR和MAPK3显示出良好的预后潜力。总的来说，PTPN11、JAK2和ESR1是重叠的差异表达枢纽靶点，参与了两种癌症的显著良好预后。结论这些差异表达的枢纽靶点由于其强大的预后潜力，可能会被考虑到未来的BC和LC治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

23 weeks

期刊介绍： Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.